A taper-oriented programme is one in which the plan for coming off the medication is written at the start of treatment rather than improvised at the end. The reasoning is straightforward: weight regain after stopping is one of the best-documented findings in this field, and the things that might blunt it — muscle that has been protected, a training habit, an eating pattern that has stopped requiring effort — take months to establish and cannot be assembled in the last few weeks. Whether designing a programme this way produces a better result than not doing so has never been trialled. What follows is the case for the approach, what it is made of, and where the evidence runs out.
Taper-oriented programme: one in which the plan for reducing and eventually stopping the medication is designed at the outset, so that whatever is meant to replace its effect has the whole treatment period to be built.
Why design the exit at the start?
Because the regain data is clear, and the replacements are slow.
Start with what happens when treatment ends. In the STEP 1 extension, participants regained about two-thirds of their lost weight within a year of stopping (Wilding 2022). SURMOUNT-4 randomised people to continue tirzepatide or switch to placebo after a 36-week lead-in: the placebo group regained 14.0% of body weight over the following year while the continuing group lost a further 5.5% (Aronne 2024). A meta-analysis of eight withdrawal trials across 2,372 participants found the same pattern across the drug class (Berg 2025). A nonlinear meta-regression across six cessation trials puts about 60% of lost weight back at one year, with the fastest regain early and the curve flattening after that (Budini 2026).
Now look at the timescales on the other side of the ledger. Measurable muscle growth from resistance training appears at around three to four weeks in previously sedentary men, with strength improving in parallel (DeFreitas 2011) — and that is the beginning of the process, not the end of it. Maintenance appears to become more durable with time held rather than immediately: a review of the maintenance literature notes that once a loss has been kept for two to five years, the chance of longer-term success rises substantially (Wing and Hill 2001).
The shape of the regain curve sharpens the point. The same meta-regression models a half-life of 23.0 weeks for the regain process, meaning the steepest part happens early and the curve flattens afterwards (Budini 2026). The months immediately after stopping are therefore the period under the most pressure — and they are also the months in which a person has the least time left to build anything new.
Put those two timescales together and the scheduling problem answers itself. The regain pressure arrives at its maximum right after stopping. The protective factors need months to years to establish. A plan that begins when the prescription ends is starting the slow process at the moment the fast one begins.
What is the plan actually made of?
Three components, each with its own evidence, and none of which is the medication.
Muscle protected throughout. In the SURMOUNT-1 body-composition sub-study, roughly 25% of the weight lost was lean mass and 75% was fat — in the tirzepatide arm and the placebo arm alike (Look 2025). Lean mass fell in absolute terms in both. That share is not fixed, and the best-evidenced way to shift it is resistance training: across 114 trials covering 4,184 people, lean mass was statistically unchanged when resistance training accompanied caloric restriction (Lopez 2022). In obese older adults specifically, six RCTs found resistance training prevented an estimated 93.5% of the lean-mass loss that caloric restriction otherwise caused, without reducing fat loss (Sardeli 2018) — an older-adult finding rather than a universal one.
The dose required is smaller than most people assume. In resistance-trained men, as little as one hard set per exercise, two to three times a week, taken to failure, produced significant strength gains over 8 to 12 weeks (Androulakis-Korakakis 2020). The authors describe that as a floor rather than a target, and it was tested in trained men rather than in beginners or in women. It is still the most useful number in the training literature for someone worried they cannot fit training in. We cover it in the minimum effective resistance training dose.
Training supplies the signal; protein supplies the material, and it is the input most likely to fall away when appetite is suppressed. Our protein guide covers the target and how to reach it on Singapore food when eating is difficult.
Habits built while they are easiest to build. Semaglutide trials using a self-report eating-control instrument found craving-control scores improved significantly versus placebo, sustained across 20, 52 and 104 weeks (STEP 5 sub-study). Those are mean differences on a self-report scale whose own authors call its validation preliminary, and they were measured with semaglutide rather than across the class. The practical implication is modest but real: the treatment period is a stretch of time when changing what and how much someone eats meets less internal resistance than it usually does. Habits formed then still have to survive afterwards, which is why they are worth forming deliberately rather than by accident.
Activity and self-monitoring that continue past the prescription. The ACSM position stand associates more than 250 minutes a week of physical activity with better maintenance on cross-sectional and prospective evidence — and states in the same document that no well-designed randomised trial exists to judge whether physical activity prevents regain (Donnelly 2009). On monitoring, registry members who reduced how often they weighed themselves regained 4.0 kg over a year against 1.1 kg in those who weighed themselves more often (Butryn 2007) — observational, in a self-selected group of people who had already succeeded.
What "a planned reduction" can and cannot mean
It can mean that a dose change is a decision made in advance with a doctor. It cannot mean a schedule published in an article.
The principle a prescriber works to is the lowest effective dose — general prescribing practice rather than a trial finding: the smallest dose that still achieves the clinical goal, rather than the highest dose a person tolerates. What that dose is differs between people, which is why it is a principle rather than a number, and why it is set by the prescribing doctor with the individual in front of them. Dose decisions depend on how someone has responded, what side effects they have had, what else they take and what the goal is.
At GetLean, a patient has a monthly check-in with Dr Quek, and dose changes are made at that check-in. A patient can raise a change at any check-in; the decision is his, taken on how the individual has responded and how well they tolerate it.
At GetLean the taper is planned from the first consultation and then set at the monthly reviews as the response comes in, rather than written as a fixed schedule on day one. The intention to end is fixed at the start; the pace follows what has actually happened.
The one thing that can be said with confidence is what the alternative looks like. Coming off with no plan means the appetite effect stops on a date and nothing has been prepared to take its place. Coming off with a plan means the training, the eating pattern and the monitoring were already running before the dose started moving. Whether the second reliably produces a better outcome than the first is the question nobody has answered — see below.
What has not been tested
The design itself.
No randomised trial has compared a taper against an abrupt stop. Every published GLP-1 withdrawal trial switched participants abruptly to placebo, so the literature describes what happens when a medication is removed and says nothing about what happens when a dose is reduced gradually. The nearest available data is a retrospective cohort from one commercial digital clinic where tapering was offered as a clinician-guided personal choice rather than randomised, reporting a mean 16.7% weight loss at week 64 on individualised dosing (Seier 2025). There is no control group, and the clinic that produced the data also sells the programme being evaluated. It establishes that clinics do this. It does not establish that it works. Tapering off GLP-1 goes through that evidence in full.
Nor could we find a study testing the wider proposition — a programme built around a planned exit against a programme that is not. So the case for the approach rests on two things: the regain evidence, which is strong, and the evidence behind the individual components, which is separately good for resistance training and weaker and largely observational for the behavioural parts. It does not rest on a head-to-head comparison, because none exists.
Continuing treatment, meanwhile, remains the option with the strongest trial evidence behind it — in SURMOUNT-4's randomised-withdrawal design, the group that kept taking the medication kept losing while the group switched to placebo regained (Aronne 2024). Staying on the medication and planning to come off it are both legitimate paths, and the choice belongs to the patient and their doctor. We set out both positions in treatment length on GLP-1: what has been tested.
At GetLean, our philosophy is that GLP-1 medication should act as a catalyst — not something to depend on indefinitely. Designing the exit from the beginning follows from that philosophy and from the regain data. It is a reasoned approach, not a proven one. Individual results vary, and clinical-trial figures describe the populations studied. Never change or stop a prescribed medication on your own; that is a conversation with the doctor who prescribed it.
Common questions
What is a taper-oriented GLP-1 programme?
One in which the plan for reducing and eventually stopping the medication is designed at the start of treatment rather than improvised at the end. The reasoning is that the things meant to replace the medication's effect — muscle, a training habit, a settled eating pattern — take months to build, so they have to be started early.
Does planning the exit early produce a better result?
That comparison has never been trialled. No study has tested a programme designed around an exit against one that is not, so there is no evidence that the design itself changes outcomes. What is established is the regain data it responds to, and the separate evidence behind its individual components.
Why not just stay on the medication?
Continuing treatment is the option with the strongest trial evidence — in SURMOUNT-4, those who continued lost a further 5.5% while those switched to placebo regained 14.0% (Aronne 2024). Staying on and coming off are both legitimate paths, and which one suits a person is a decision for them and their doctor.
How long does it take to build the things that replace the medication?
Longer than the final few weeks of treatment. Measurable muscle growth appears at around three to four weeks of resistance training in previously sedentary men (DeFreitas 2011), and maintenance appears to become more durable only after a loss has been held for two to five years (Wing and Hill 2001).
Is tapering the dose evidence-based?
No. Every published GLP-1 withdrawal trial used an abrupt switch to placebo, and no randomised trial has compared a gradual dose reduction against stopping outright. Dose decisions belong to the prescribing doctor, and no article should offer a schedule.